These 2 Nuclear Stocks Are Set to Soar This Fall and Beyond

Rising uranium prices (about $94/lb currently, Citi sees at least $100/lb this year) and IAEA projections that nuclear capacity could expand up to 2.6x by 2050 underpin bullish case for Cameco and NuScale. Cameco, the world’s No.2 uranium miner, is restarting idled mines, holds a 49% stake in Westinghouse via a Brookfield partnership, and faces analyst-expected 2024–2027 revenue and EPS CAGRs of 9% and 91% respectively (trading at ~69x this year’s earnings). NuScale, a small modular reactor developer, has a TVA contract to deploy up to 6 GW (online by ~2032), a Romania FEED subcontract (462 MWe), and is forecast to grow revenue more than sevenfold from 2025–2027 (priced at ~37x 2024 sales), making it a speculative, high-growth play on next-gen nuclear deployment.

Analysis

Market structure: Rising spot uranium (~$94/lb, Citi >$100 target) benefits integrated miners (CCJ), toll-millers and diversified owners (BAM via Westinghouse) while pressuring marginal higher-cost producers and short-term utility buyers. SMR developers (SMR) change the projectable demand curve by lowering initial capex and siting constraints, but meaningful load replacement and merchant revenue won’t materialize until the 2030s, leaving near-term winners in commodity & services, not reactor builders.

Risk assessment: Tail risks include a policy reversal (nuclear phase-outs), a major reactor incident, or Kazakhstan/secondary supply re-entering the market — any could drop spot uranium >30% rapidly. Time horizons matter: days-weeks = spot volatility; 3–12 months = mine restarts and contract renegotiations; 2027–2035 = capacity build-out and SMR commercialization. Hidden dependencies include Westinghouse integration execution (CCJ 49% stake) and utility balance-sheet tolerance for multi‑year capex.

Trade implications: Favor commodity exposure with controlled operational risk and conservatively sized SMR optionality. Use size and structure to reflect timing: miners for 6–24 months, SMR binary LEAP exposure for 3–10 years; capital providers (BAM, FLR) are second-order beneficiaries. Cross-asset: sustained uranium inflation would modestly tighten credit for utilities and push longer-term government borrowing to fund grid upgrades.

Contrarian angles: Consensus underweights execution and inventory dynamics — a repeat of 2007-style price spike then collapse is plausible if mine restarts overshoot or strategic reserves sell. SMR valuations (37x sales) embed commercialization certainty that political, permitting, or supply-chain delays can easily erode; conversely, a confirmed FID (Romania/TVA milestones) could re-rate SMR materially.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in CCJ within the next 2 weeks to capture uranium upside; size a hedge by allocating 50% of that exposure to a 12-month call spread (buy 12‑month ATM calls, sell 40–60% OTM calls) to cap cost. Trim to 0% if spot uranium closes below $70 for 30 consecutive days or CCJ equity falls >25% from entry.
• Initiate a tactical, high-conviction optionality position in SMR via 2028–2029 LEAP calls (limit to 0.5–1% portfolio risk) rather than large equity exposure; add up to a total 2% equity only after two binary catalysts: (1) Romanian RoPower FID executed, and (2) TVA final permitting milestone cleared — otherwise maintain time-decay-limited exposure.
• Run a pair trade: long CCJ (2%) vs short SMR (1–1.5% notional) for 6–12 months to exploit commodity-led upside vs execution/valuation risk. Close or rebalance if uranium >$120 or if SMR announces funded multi-GW procurement/firm engineering contracts.
• Monitor four triggers in the next 90 days and act: Kazakhstan production notices (±5% supply), US DoE/strategic uranium reserve announcements, Westinghouse integration KPIs from BAM/CCJ quarterly reports, and TVA/RoPower FID dates — any affirmative trigger justifies scale-up, negative trigger mandates de-risking.